date,title,source
Nov-14-18,Diffusion Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update,GlobeNewswire
Nov-15-18,Diffusion Pharmaceuticals Chief Scientific Officer Dr. John L. Gainer to Present at 2018 Annual Meeting of the Society for NeuroOncology,GlobeNewswire
Dec-10-18,DFFN: Phase 2 Clinical Trial of TSC in Acute Stroke to Commence in 2019,Zacks Small Cap Research
Dec-13-18,Diffusion Pharmaceuticals Announces 1-for-15 Reverse Stock Split As Part Of NASDAQ Compliance Plan,GlobeNewswire
Dec-17-18,4 Stocks Providing Investor Opportunity Right Now,ACCESSWIRE
Dec-17-18,U.S. Patent Office Awards Diffusion Exclusive Rights for Use of TSC in Conjunction with Only FDA-Approved Stroke Therapeutic,GlobeNewswire
Dec-18-18,Today's Research Reports on Trending Tickers: Evofem Biosciences and Diffusion Pharmaceuticals,ACCESSWIRE
Jan-03-19,Diffusion Pharmaceuticals Executes Successful NASDAQ Compliance Plan: Company Will Remain Listed on NASDAQ Stock Market,GlobeNewswire
Jan-04-19,Diffusion Pharmaceuticals Chief Executive Officer David Kalergis to Present at 37th Annual J.P. Morgan Healthcare Conference,GlobeNewswire
Jan-22-19,How Does Investing In Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Impact The Volatility Of Your Portfolio?,Simply Wall St.
